Impact of a Smartphone-Based Artificial Intelligence Platform on Hepatitis C Adherence in a Real-World Population

In this video Rich Christie MD PhD discusses:

There are an estimated 2.4 million people living with hepatitis C (HCV) in the United States.
Although adherence to new regimens is typically quite good, non-adherence to treatment remains the biggest risk factor for treatment failure and thus a future need for retreatment.
There has been research demonstrating that administration of directly observed therapy (DOC) have improved adherence in outcomes when used in other infectious diseases, however, managed care plans would be challenged to enact such a requirement across a population.
Past research has also demonstrated that the use of an artificial intelligence platform (AIP*) embedded within a mobile app to digitally mimic DOC led to high rates of treatment completion and adherence levels in participating patients.
Digital tools that are able to accurately measure adherence in real-time, can also lead to more timely interventions to address adherence barriers.
Despite this evidence, there remains limited research available on patient’s willingness to use such a tool and how it would impact outcomes in a real-world population.
To help answer this question, a pilot program was implemented in members initiating oral HCV therapy, in which members had the choice to use AIP* that visually and automatically confirmed participant identity, the medication, and medication ingestion.